2:44 PM Eastern Daylight Time May 28, 2013
14:44 EDT - Amarin (AMRN) bull Citi says investors should be buying the biotech in the wake of today's selloff prompted by AstraZeneca's (AZN) planned takeover of AMRN rival Omthera (OMTH). "While the initial reaction may be 'why not AMRN?' we think a more-meaningful takeaway is the positive indication this deal reflects on future utility for" the class of cardiovascular omega-3 drugs that AMRN is being acquired for." Citi notes OMTH's market cap is way below AMRN's $1B. Shares fall 6.1% to $6.37 after earlier hitting a 17-month low.